Stock comparison
ResMed
Summit Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.44B
Sector
Healthcare
SMMT
Summit Therapeutics
Market cap
$13.87B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | SMMT | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 14F | RMD |
| Benjamin Graham | 75B | 54D | RMD |
| Philip Fisher | 75B | 46D | RMD |
| Peter Lynch | 58C | 64C | SMMT |
| Joel Greenblatt | 47D | 0F | RMD |
| Charlie Munger | 69B | 20F | RMD |
| Terry Smith | 73B | 19F | RMD |
Side-by-side metrics
| Metric | RMD | SMMT |
|---|---|---|
| Market cap | $30.44B | $13.87B |
| P/E (TTM) | 19.6x | - |
| EV/EBIT | 17.1x | - |
| ROIC (TTM) | 19.63% | -2.48% |
| Gross margin | 61.69% | 0.0% |
| Net margin | 27.44% | 0.0% |
| Revenue CAGR 5y | 12.64% | - |
| EPS CAGR 5y | 30.73% | 39.68% |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- ROIC (TTM)19.63%vs -2.48%+108%
- Gross margin61.69%vs 0.0%+100%
- Net margin27.44%vs 0.0%+100%
- Dividend yield1.14%vs 0.0%+100%
SMMT leads on
- EV/EBIT-vs 17.1x+170%
- P/E (TTM)-vs 19.6x+163%
- Debt / Equity0.0xvs 0.1x+72%
- EPS CAGR 5y39.68%vs 30.73%+23%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.